Publication of interim report January – March 2026

▤ Summary

Genetic Analysis AS published its interim report for January to March 2026 and said it made continued progress in the first quarter. The company grew recurring GA-map reagent kit sales and advanced its microbiome-based diagnostics pipeline. It also launched GA-map Dysbiosis Test AInsight, an AI-assisted interpretation platform for microbiome results, and highlighted new patent protections in Canada and the United States. Revenue rose year over year, while EBITDA remained negative and cash and cash equivalents declined to NOK 20.0 million at quarter end. The company continues to focus on partner laboratories, reagent-kit sales, and new diagnostic applications.

▦ Linked Companies